The Air Force Research Laboratory (AFRL) awarded Varda Space Industries a $48 million firm, fixed-price, indefinite-delivery/indefinite-quantity contract under the "Prometheus" program to test military payloads on reentry capsules at hypersonic speeds. The four-year contract, running through May 2028, leverages Varda's W-Series reentry capsules as low-cost, high-cadence testbeds for military reentry experiments -- capsules that reenter Earth's atmosphere at speeds exceeding Mach 25.
AFRL described Prometheus as addressing "a national security need to accelerate the ability to conduct novel science and technology experiments in the extreme reentry environment." The program gives the military an operational environment to test vehicle subsystems -- thermal protection, navigation, sensor performance -- under real hypersonic flight conditions, at a fraction of the cost of traditional hypersonic test flights.
The Dual-Use Architecture
Varda was founded in January 2021 by Will Bruey (former SpaceX electrical engineer) and Delian Asparouhov (partner at Founders Fund) to manufacture pharmaceuticals in microgravity. The company's W-Series reentry capsules are designed to carry pharmaceutical experiments to orbit and return them to Earth. But reentry capsules that survive Mach 25+ atmospheric reentry are, by definition, hypersonic vehicles -- and the same engineering that enables pharmaceutical delivery from space enables hypersonic weapons testing for the Pentagon.
This dual-use architecture is not incidental. Varda's defense portfolio now includes:
The Thiel Connection
Varda's co-founder Delian Asparouhov is a partner at Founders Fund, Peter Thiel's venture firm. This is not an arm's-length relationship -- Asparouhov simultaneously serves as president of Varda and as a Founders Fund partner, meaning Thiel's firm is investing in a company run by one of its own partners.
Investment history:
The Hypersonic Weapons Pipeline
The Prometheus contract and MACH-TB selection place Varda squarely in the Pentagon's hypersonic weapons development ecosystem. The MACH-TB program was initiated in 2022 in response to Chinese and Russian hypersonic weapons advances. Task Area 1 went to Kratos Defense under a $1.45 billion five-year contract. Varda's selection for Task Area 3 puts a Thiel-connected startup alongside major defense contractors in one of the Pentagon's highest-priority weapons programs.
The pharmaceutical manufacturing narrative provides commercial justification and public relations cover for what is simultaneously a military reentry vehicle program. Every W-Series capsule that demonstrates successful hypersonic reentry carrying pharmaceutical payloads also demonstrates capability relevant to military reentry vehicles, hypersonic glide bodies, and weapons delivery systems. The Pentagon is effectively subsidizing the development of Varda's core technology while the company's pharmaceutical business provides the civilian market story.
This mirrors the broader Thiel portfolio pattern: Palantir built data analytics for the intelligence community while marketing to commercial clients; Anduril builds autonomous weapons systems while marketing border security; Varda manufactures drugs in space while testing hypersonic reentry vehicles for the Air Force.